These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 19671047)

  • 21. Development of Inhibitors Targeting Hypoxia-Inducible Factor 1 and 2 for Cancer Therapy.
    Yu T; Tang B; Sun X
    Yonsei Med J; 2017 May; 58(3):489-496. PubMed ID: 28332352
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The intriguing interplay between therapies targeting the epidermal growth factor receptor, the hypoxic microenvironment and hypoxia-inducible factors.
    Wouters A; Boeckx C; Vermorken JB; Van den Weyngaert D; Peeters M; Lardon F
    Curr Pharm Des; 2013; 19(5):907-17. PubMed ID: 22973959
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hypoxia-inducible factor (HIF) inhibitors: a patent survey (2011-2015).
    Ban HS; Uto Y; Won M; Nakamura H
    Expert Opin Ther Pat; 2016; 26(3):309-22. PubMed ID: 26882240
    [TBL] [Abstract][Full Text] [Related]  

  • 24. MiR-338-3p inhibits hepatocarcinoma cells and sensitizes these cells to sorafenib by targeting hypoxia-induced factor 1α.
    Xu H; Zhao L; Fang Q; Sun J; Zhang S; Zhan C; Liu S; Zhang Y
    PLoS One; 2014; 9(12):e115565. PubMed ID: 25531114
    [TBL] [Abstract][Full Text] [Related]  

  • 25. AK-1, a SIRT2 inhibitor, destabilizes HIF-1α and diminishes its transcriptional activity during hypoxia.
    Lee SD; Kim W; Jeong JW; Park JW; Kim JE
    Cancer Lett; 2016 Apr; 373(1):138-145. PubMed ID: 26808575
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The role of hypoxia-inducible factor-1α and -2α in androgen insensitive prostate cancer cells.
    Jeong CW; Yoon CY; Jeong SJ; Hong SK; Byun SS; Kwak C; Lee SE
    Urol Oncol; 2013 Nov; 31(8):1448-56. PubMed ID: 22537539
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The transcriptional factors HIF-1 and HIF-2 and their novel inhibitors in cancer therapy.
    Albadari N; Deng S; Li W
    Expert Opin Drug Discov; 2019 Jul; 14(7):667-682. PubMed ID: 31070059
    [No Abstract]   [Full Text] [Related]  

  • 28. Low Molecular Weight Fucoidan Inhibits Tumor Angiogenesis through Downregulation of HIF-1/VEGF Signaling under Hypoxia.
    Chen MC; Hsu WL; Hwang PA; Chou TC
    Mar Drugs; 2015 Jul; 13(7):4436-51. PubMed ID: 26193287
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The novel hypoxia-inducible factor-1α inhibitor IDF-11774 regulates cancer metabolism, thereby suppressing tumor growth.
    Ban HS; Kim BK; Lee H; Kim HM; Harmalkar D; Nam M; Park SK; Lee K; Park JT; Kim I; Lee K; Hwang GS; Won M
    Cell Death Dis; 2017 Jun; 8(6):e2843. PubMed ID: 28569777
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Development of novel inhibitors targeting HIF-1α towards anticancer drug discovery.
    Yewalkar N; Deore V; Padgaonkar A; Manohar S; Sahu B; Kumar P; Jalota-Badhwar A; Joshi KS; Sharma S; Kumar S
    Bioorg Med Chem Lett; 2010 Nov; 20(22):6426-9. PubMed ID: 20932758
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Shikonin suppresses proliferation and induces cell cycle arrest through the inhibition of hypoxia-inducible factor-1α signaling.
    Li MY; Mi C; Wang KS; Wang Z; Zuo HX; Piao LX; Xu GH; Li X; Ma J; Jin X
    Chem Biol Interact; 2017 Aug; 274():58-67. PubMed ID: 28684144
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hypoxia inducible factor pathway inhibitors as anticancer therapeutics.
    Burroughs SK; Kaluz S; Wang D; Wang K; Van Meir EG; Wang B
    Future Med Chem; 2013 Apr; 5(5):553-72. PubMed ID: 23573973
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Small-molecule inhibitors of the HIF pathway and synthetic lethal interactions.
    Jones DT; Harris AL
    Expert Opin Ther Targets; 2012 May; 16(5):463-80. PubMed ID: 22512262
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of YC-1 on hypoxia-inducible factor 1 alpha in hypoxic human bladder transitional carcinoma cell line T24 cells.
    Li Y; Zhao X; Tang H; Zhong Z; Zhang L; Xu R; Li S; Wang Y
    Urol Int; 2012; 88(1):95-101. PubMed ID: 22041818
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hypoxia-inducible factor-1 as a therapeutic target in cancer.
    Tang CM; Yu J
    J Gastroenterol Hepatol; 2013 Mar; 28(3):401-5. PubMed ID: 23173651
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Is the hypoxia-inducible factor pathway important in gastric cancer?
    Griffiths EA; Pritchard SA; Welch IM; Price PM; West CM
    Eur J Cancer; 2005 Dec; 41(18):2792-805. PubMed ID: 16290133
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identification of thioredoxin-interacting protein 1 as a hypoxia-inducible factor 1alpha-induced gene in pancreatic cancer.
    Baker AF; Koh MY; Williams RR; James B; Wang H; Tate WR; Gallegos A; Von Hoff DD; Han H; Powis G
    Pancreas; 2008 Mar; 36(2):178-86. PubMed ID: 18376310
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Overcoming cisplatin resistance of ovarian cancer cells by targeting HIF-1-regulated cancer metabolism.
    Ai Z; Lu Y; Qiu S; Fan Z
    Cancer Lett; 2016 Apr; 373(1):36-44. PubMed ID: 26801746
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy.
    Semenza GL
    Trends Pharmacol Sci; 2012 Apr; 33(4):207-14. PubMed ID: 22398146
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cellular redox status regulates hypoxia inducible factor-1 activity. Role in tumour development.
    Martínez-Sánchez G; Giuliani A
    J Exp Clin Cancer Res; 2007 Mar; 26(1):39-50. PubMed ID: 17550131
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.